Jeffrey A. Stanley

Jeffrey A. Stanley, Ph.D.

Associate Professor
Director of MR Operations
Department of Psychiatry and Behavioral Neurosciences
Wayne State University School of Medicine
University Health Center 9B-28
4201 St. Antoine Street, Detroit, MI 48201

E mail: jstanley@med.wayne.edu

Phone: (313) 577-9090

Fax: (313) 577-5900

Research Interests:

Investigate possible metabolite differences in specific brain regions of children with attention deficit hyperactive disorder (ADHD) compare with healthy children that may reflect an underdevelopment of neuronal processes using in vivo proton and phosphorus MR spectroscopy.

Obtain a better understanding of profiling regional metabolite levels as the brain develops in children, adolescents and in young adults, which is critical when investigating neurodevelopmental disorders.

Gain a better understanding of the molecular pathophysiology of schizophrenia and of subjects with increased genetic risk for schizophrenia using in vivo proton and phosphorus spectroscopy. This also includes investigating possible factors such as onset age, co-morbidity and cognitive impairment that influences the degree of metabolite alteration in the brain of schizophrenia subjects.

Investigate possible improvements in in vivo biochemical, peripheral measurements of essential fatty acids, and attention performance of ADHD children following a dietary supplementation of a specific essential fatty acid.

Better the understanding of the physiological role of N-acetylaspartate (NAA) in schizophrenia by improving the quantification approach and by quantifying its relaxation parameters.

Segregate and quantify the broad underlying spectral component of in vivo ³¹P MRS data, which provides additional information about the membrane phospholipids. By studying the profile of these metabolites during normal development, neurodevelopmental abnormalities in schizophrenia can then be assessed.

Current Research:

R01 MH65420                              Jeffrey A. Stanley, Ph.D. (P.I.)                                    7/28/03 - 6/30/06

NIMH                                             $450,000

“In Vivo ³¹P Spectroscopy and MRI in ADHD” The purpose of this study is to identify regional molecular/metabolic alterations in treatment naïve children with ADHD compared to a matched control group of healthy children using in vivo phosphorus spectroscopy and MRI.

Role: Principal Investigator

R01 MH64023                              Matcheri Kashavan, M.D. (P.I.)                                   12/1/02 - 11/30/07

NIMH                                             $2,228,395

“Brain Maturation and Vulnerability to Schizophrenia” Brain maturation and vulnerability to schizophrenia will seek to obtain convergent evidence for structural and functional integrity of HAC and subcortical brain structures.

Role: Co-Investigator

Publications:

Selected Peer-Reviewed Publications (in chronological order)

Stanley JA, Williamson PC, Drost DJ, Carr T, Rylett RJ, Morrison-Stewart S, and Thompson RT. Membrane phospholipid metabolism and schizophrenia: An in vivo ³¹P MR spectroscopy study. Schizo. Res., 13:209-215, 1994.

Stanley JA, Williamson PC, Drost DJ, Carr T, Rylett RJ, Malla A, and Thompson RT. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch. Gen. Psych., 52:399-406, 1995.

Stanley JA, Drost DJ, Williamson PC, and Thompson RT. The use of a priori knowledge to quantify short echo in vivo ¹H MR spectra. Magn. Reson. Med., 34:17-24, 1995.

Stanley JA, Williamson PC, Drost DJ, Rylett RJ, Carr T, Malla A, and Thompson RT. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizo. Bull., 22:597-609, 1996.

Cendes F, Stanley JA, Dubeau F, Andermann F, and Arnold DL. Proton MR spectroscopic imaging for discrimination of absence and complex partial seizures. Ann. Neurol., 41:74-81,1997.

Klunk WE, Xu CJ, McClure RJ, Panchalingam K, Stanley JA and Pettegrew JW. Aggregation of beta-amyloid peptide is promoted by membrane phospholipid metabolites elevated in Alzheimer's disease brain. J. Neurochem., 97:266-272, 1997.

Pettegrew JW, Klunk WE, Panchalingam K, McClure RJ and Stanley JA. Magnetic resonance spectroscopic changes in Alzheimer’s disease. Ann. NY Acad. Sci., 826:282-306, 1997.

De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley J, Francis GS, Antel JP and Arnold DL. Axonal damage correlates with disability in patients with relapsing- remitting multiple sclerosis: Results of a longitudinal magnetic resonance spectroscopy study. Brain, 121:1469-77, 1998.

Stanley JA, Cendes F, Dubeau F, Andermann F, and Arnold DL. Proton magnetic resonance spectroscopic imaging in patients with extratemporal epilepsy. Epilepsia, 39:267-273, 1998.

Klunk WE, Panchalingam K, McClure RJ, Stanley JA and Pettegrew JW. Metabolic alterations in post-mortem Alzheimer’s disease brain are exaggerated by Apo-E4. Neurobiol. Aging, 19:511-515, 1999.

Keshavan MS, Stanley JA, Pettegrew JW. Magnetic resonance spectroscopy in schizophrenia: Methodological issues and findings – Part II. Biological Psychiatry 2000; 48:369-380.

Stanley JA, Pettegrew JW, Keshavan MS. Magnetic resonance spectroscopy in schizophrenia: Methodological issues and findings - Part I. Biological Psychiatry 2000; 48:357-368.

Pettegrew JW, Klunk WE, Panchalingam K, McClure RJ and Stanley JA. Molecular insights into neurodevelopmental and neurodegenerative diseases. Brain Res. Bull., 53:455-469, 2000.

Stanley JA and Pettegrew JW: Postprocessing method to segregate and quantify the broad components underlying the phosphodiester spectral region of in vivo ³¹P brain spectra. Magn Reson Med 2001; 45:390-396.

Brambilla P, Stanley JA, Nicoletti M, Harenski K, Wells KF, Mallinger AG, Keshavan MS, Soares JC. ¹H MRS brain measures and acute lorazepam administration in healthy human subjects. Neuropsychopharmacology 2002; 26:546-551.

Pettegrew JW, Levine J, Gershon S, Stanley JA, Servan-Schreiber D, Panchalingam K and McClure RJ. 31P-MRS study of acetyl-L-carnitine treatment in geriatric depression: preliminary results. Bipolar Disord 2002, 4:61-6.

Stanley JA. In vivo magnetic resonance spectroscopy and its application to neuropsychiatric disorders. Can. J. Psychiatry 2002, 47:315-26.

Yao JK, Stanley JA, Reddy RD, Keshavan MS and Pettegrew JW. Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites. Biol. Psychiatry 2002, 52:823-30.

Keshavan MS, Stanley JA, Montrose DM, Minshew NJ and Pettegrew JW. Prefrontal membrane phoshpolipid metabolism of child and adolescent offspring at risk for schizophrenia or schizoaffective disorder: an in vivo ³¹P MRS study. Molecular Psychiatry 2003, 8(3):316-23.

Brambilla P, Stanley JA, Sassi RB, Nicoletti M, Mallinger AG, Keshavan MS and Soares JC. 1H MRS study of dorso-lateral prefrontal cortex in healthy individuals before and after lithium administration. Neuropsychopharmacology, 29:1918-24, 2004.

Keshavan MS, Diwadkar VA, Montrose DM, Stanley JA, Pettegrew JW: Premorbid characterization in schizophrenia: the Pittsburgh High Risk Study. World Psychiatry 2004; 3(3):163-168.

Brambilla P, Stanley JA, Nicoletti MA, Sassi RB, Mallinger AG, Frank E, Kupfer D, Keshavan MS, Soares JC: ¹H magnetic resonance spectroscopy investigation of the dorsolateral prefrontal cortex in bipolar disorder patients. J Affect Disord 2005; 86(1):61-7.

Brambilla P, Stanley JA, Nicoletti MA, Sassi RB, Mallinger AG, Frank E, Kupfer DJ, Keshavan MS, Soares JC: ¹H Magnetic resonance spectroscopy study of dorsolateral prefrontal cortex in unipolar mood disorder patients. Psychiatry Res 2005; 138(2):131-9.

Frey BN, Folgierini M, Nicoletti M, Machado-Vieira R, Stanley JA, Soares JC, Kapczinski F: A proton magnetic resonance spectroscopy investigation of the dorsolateral prefrontal cortex in acute mania. Hum Psychopharmacol 2005; 20(2):133-139.

Caetano SC, Fonseca M, Olvera RL, Nicoletti M, Hatch JP, Stanley JA, Hunter K, Lafer B, Pliszka SR, Soares JC: Proton spectroscopy study of the left dorsolateral prefrontal cortex in pediatric depressed patients. Neurosci Lett 2005; 384(3):321-6.

Books and/or Chapters

Stanley JA, Williamson PC, Drost DJ, and Carr T. The study of glutamate and schizophrenia via proton MR spectroscopy. In: Nasrallah H.A., and Pettegrew J.W. (eds),. NMR Spectroscopy in Psychiatric Brian Disorders. Washington, DC: American Psychiatric Press, 21-44, 1995.

Williamson PC, Drost DJ, Stanley JA, and Carr T. Phosphorus 31 magnetic resonance spectroscopy (³¹P MRS) in schizophrenia. In: Nasrallah H.A., and Pettegrew J.W. (eds.), NMR in Psychiatric Brian Disorders. Washington, DC: American Psychiatric Press, 107-130, 1995.

Pettegrew JW, Keshavan MS, Stanley JA, McClure RJ, Johnson CR, Panchalingam K. Magnetic resonance spectroscopy in the assessment of phospholipids metabolism in schizophrenia and other psychiatric disorders. In: Peet M, Glen I, Horrobin D eds. Phospholipid Spectrum Disorder in Psychiatry and Neurology. Marius Press, 2003

WAYNE STATE UNIVERSITY | SITE MAP